Romania · Delayed Price · Currency is RON S.C. Ropharma Statistics
Total Valuation
S.C. Ropharma has a market cap or net worth of RON 103.28 million. The enterprise value is 228.28 million.
| Market Cap | 103.28M |
| Enterprise Value | 228.28M |
Important Dates
The next confirmed earnings date is Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
S.C. Ropharma has 511.27 million shares outstanding.
| Current Share Class | 511.27M |
| Shares Outstanding | 511.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 14.07% |
| Owned by Institutions (%) | 8.61% |
| Float | 177.64M |
Valuation Ratios
The trailing PE ratio is 50.50.
| PE Ratio | 50.50 |
| Forward PE | n/a |
| PS Ratio | 0.07 |
| PB Ratio | 0.39 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | 1.80 |
| P/OCF Ratio | 1.42 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.91, with an EV/FCF ratio of 3.98.
| EV / Earnings | 104.65 |
| EV / Sales | 0.15 |
| EV / EBITDA | 3.91 |
| EV / EBIT | 8.82 |
| EV / FCF | 3.98 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.63.
| Current Ratio | 1.05 |
| Quick Ratio | 0.63 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 2.90 |
| Debt / FCF | 2.95 |
| Interest Coverage | 5.24 |
Financial Efficiency
Return on equity (ROE) is 2.60% and return on invested capital (ROIC) is 2.06%.
| Return on Equity (ROE) | 2.60% |
| Return on Assets (ROA) | 1.64% |
| Return on Invested Capital (ROIC) | 2.06% |
| Return on Capital Employed (ROCE) | 6.74% |
| Weighted Average Cost of Capital (WACC) | 2.91% |
| Revenue Per Employee | 878,345 |
| Profits Per Employee | 1,246 |
| Employee Count | 1,751 |
| Asset Turnover | 1.56 |
| Inventory Turnover | 5.17 |
Taxes
In the past 12 months, S.C. Ropharma has paid 15.33 million in taxes.
| Income Tax | 15.33M |
| Effective Tax Rate | 69.12% |
Stock Price Statistics
The stock price has increased by +20.24% in the last 52 weeks. The beta is 0.35, so S.C. Ropharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +20.24% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.19 |
| Relative Strength Index (RSI) | 51.48 |
| Average Volume (20 Days) | 71,967 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, S.C. Ropharma had revenue of RON 1.54 billion and earned 2.18 million in profits. Earnings per share was 0.00.
| Revenue | 1.54B |
| Gross Profit | 323.16M |
| Operating Income | 25.89M |
| Pretax Income | 22.17M |
| Net Income | 2.18M |
| EBITDA | 44.38M |
| EBIT | 25.89M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 58.13 million in cash and 169.20 million in debt, with a net cash position of -111.07 million or -0.22 per share.
| Cash & Cash Equivalents | 58.13M |
| Total Debt | 169.20M |
| Net Cash | -111.07M |
| Net Cash Per Share | -0.22 |
| Equity (Book Value) | 266.84M |
| Book Value Per Share | 0.49 |
| Working Capital | 30.55M |
Cash Flow
In the last 12 months, operating cash flow was 72.83 million and capital expenditures -15.43 million, giving a free cash flow of 57.40 million.
| Operating Cash Flow | 72.83M |
| Capital Expenditures | -15.43M |
| Depreciation & Amortization | 18.49M |
| Net Borrowing | -5.94M |
| Free Cash Flow | 57.40M |
| FCF Per Share | 0.11 |
Margins
Gross margin is 21.01%, with operating and profit margins of 1.68% and 0.14%.
| Gross Margin | 21.01% |
| Operating Margin | 1.68% |
| Pretax Margin | 1.44% |
| Profit Margin | 0.14% |
| EBITDA Margin | 2.89% |
| EBIT Margin | 1.68% |
| FCF Margin | 3.73% |
Dividends & Yields
S.C. Ropharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 2.11% |
| FCF Yield | 55.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
S.C. Ropharma has an Altman Z-Score of 1.88 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.88 |
| Piotroski F-Score | 5 |